Product Images Asenapine

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 16 images provide visual information about the product associated with Asenapine NDC 59762-2012 by Greenstone Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

The chemical structure for Asenapine sublingual tablets contain asenapine maleate which is an atypical antipsychotic that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-2-butenedioate (1:1). Its molecular formula is C17H16ClNOC4H4O4 and its molecular weight is 401.84 (free base: 285.8). - asenapine 01

The chemical structure for Asenapine sublingual tablets contain asenapine maleate which is an atypical antipsychotic that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c]pyrrole (2Z)-2-butenedioate (1:1). Its molecular formula is C17H16ClNOC4H4O4 and its molecular weight is 401.84 (free base: 285.8). - asenapine 01

Figure 1 - asenapine 02

Figure 1 - asenapine 02

This appears to be a table displaying the effects (inhibitor or inducer) of various substances on different enzymes, based on their Cmax and AUC values. The enzymes mentioned include CYPIAZ, CYPIAZAC, CYRD6, CYPIALADNIAL, CYP3AY and UGTIAG. It is unclear what the numbers in the last row represent as the text is cut off.*

Figure 2 - asenapine 03

Figure 2 - asenapine 03

This text describes the effects of Ascnapine on the metabolism of Paroxetine and Imipramine in healthy individuals. Ascnapine appears to be a weak inhibitor of CYP206, which is a marker of CYP2D6 activity. Treatment with Ascnapine decreased the DX/DA ratio indicating CYP2D6 inhibition. Paroxetine treatment also decreased the DX/DM ratio. Co-administration of a single 75 mg dose of Imipramine with a single 3 mg dose of Ascnapine did not affect the plasma concentrations of the metabolite Desipramine which is a CYP2D6 substrate. The text provides information on the substrates and inhibitors for CYP2D6, CYP1A2, CYP19/3A4, and their effects on AUC and Cmax.*

Figure 3 - asenapine 04

Figure 3 - asenapine 04

Figure 4 - asenapine 05

Figure 4 - asenapine 05

Figure 5 - asenapine 06

Figure 5 - asenapine 06

Tablet Pack - asenapine 07

Tablet Pack - asenapine 07

Figure A - asenapine 08

Figure A - asenapine 08

Figure B - asenapine 09

Figure B - asenapine 09

Figure C - asenapine 0a

Figure C - asenapine 0a

Figure D - asenapine 0b

Figure D - asenapine 0b

Figure E - asenapine 0c

Figure E - asenapine 0c

Figure F - asenapine 0d

Figure F - asenapine 0d

PRINCIPAL DISPLAY PANELasenapine sublingual tablets2.5 mg60 TabletsBlack Cherry FlavorRx Only - asenapine 0e

PRINCIPAL DISPLAY PANELasenapine sublingual tablets2.5 mg60 TabletsBlack Cherry FlavorRx Only - asenapine 0e

PRINCIPAL DISPLAY PANELasenapine sublingual tablets5 mg60 TabletsBlack Cherry FlavorRx Only - asenapine 0f

PRINCIPAL DISPLAY PANELasenapine sublingual tablets5 mg60 TabletsBlack Cherry FlavorRx Only - asenapine 0f

PRINCIPAL DISPLAY PANELasenapine sublingual tablets10 mg60 TabletsBlack Cherry FlavorRx Only - asenapine 10

PRINCIPAL DISPLAY PANELasenapine sublingual tablets10 mg60 TabletsBlack Cherry FlavorRx Only - asenapine 10

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.